Magnesium Evolution — Scientific Dossier
INGREDIENT DOSSIER
Magnesium Evolution™ Scientific Dossier
A review of multi-pathway magnesium delivery — comparing four magnesium technologies by absorption kinetics, tissue targeting, and the physiological case for splitting them across an immediate- and delayed-release phase.
Why magnesium form matters
Total dose is only half the story — the body doesn't use magnesium the same way everywhere.
Magnesium participates in more than 300 enzymatic reactions spanning neuromuscular function, mitochondrial energy production, neurotransmission, sleep physiology, and cardiovascular function. But brain, muscle, heart, bone, and mitochondria each rely on different transporters, uptake kinetics, and tissue affinities — so a single magnesium salt, delivered all at once, may not serve every compartment equally well.
| System | Primary magnesium demand |
|---|---|
| Brain | Neuronal magnesium status |
| Muscle | ATP production, recovery |
| Heart | Electrophysiology |
| Bone | Mineral reservoir |
| Mitochondria | Oxidative metabolism |
| Sleep pathways | GABA modulation |
That's the rationale for a multi-form, multi-kinetic strategy rather than a single magnesium salt at a single dose.
Albion® magnesium bisglycinate chelate
The foundational, most extensively studied organic magnesium form in this system.
Magnesium bound to two glycine molecules forms a chelated complex that resists ionization in the intestinal lumen, allowing amino-acid-transporter-mediated uptake rather than relying on passive mineral absorption alone — the basis for its comparatively strong tolerability and reduced laxative effect versus inorganic salts.
Bisglycinate in adults with poor sleep
Randomized, double-blind, placebo-controlled. Magnesium bisglycinate produced a statistically significant improvement in Insomnia Severity Index scores versus placebo — described by the authors as a modest effect, strongest in participants with lower baseline dietary magnesium intake.
Dose-dependent absorption profile
Companion study to the delayed-release research below, from the same research group — characterizing how absorption of different magnesium compounds scales with dose.
Magnesium acetyl taurate
Magnesium paired with acetylated taurine — positioned for neuronal uptake and rapid tissue penetration.
Taurine itself participates in GABAergic signalling, calcium regulation, neuronal membrane stabilization, and cardiovascular electrophysiology — the rationale for describing magnesium acetyl taurate as offering dual physiological activity rather than magnesium delivery alone.
Acetyl taurate vs. L-threonate
This is the comparative study behind the "outperforms L-threonate" claim — and it's real, current, and worth featuring, with one caveat worth keeping visible: it's a rat study, not a human trial. MAT (and the MAT+MLT combination) produced significantly greater tissue Mg²⁺ accumulation and stronger upregulation of BDNF, CREB, synaptophysin, and PSD-95 than MLT alone, alongside improved antioxidant markers (SOD, glutathione, CoQ10) and mitochondrial ETC complex activity. Magnesium L-threonate itself has separate, more extensive human RCT data (branded Magtein®) than magnesium acetyl taurate currently does — worth knowing if a direct comparison ever gets scrutinized.
Brain tissue concentration, head-to-head
In a direct comparison of five magnesium compounds in rats, acetyl taurate was rapidly absorbed, crossed into the brain easily, and reached the highest brain tissue concentration of any form tested — with decreased anxiety-indicator behavior alongside it. More on this study below: it's also the clearest available explanation for the immediate/delayed-release split.
Aquamin® magnesium
Marine-derived magnesium from Lithothamnion algae, carrying a broad complement of trace minerals alongside the magnesium itself.
Bioaccessibility vs. magnesium oxide & chloride
Aquamin-Mg bioaccessibility and transport across the intestinal cell model was significantly greater than magnesium oxide, and comparable to the more bioavailable magnesium chloride — an in-vitro result, not a human feeding study, but a clean head-to-head against two common commercial forms.
Beyond magnesium itself, Aquamin contributes dozens of naturally co-occurring trace minerals — proposed to support physiological magnesium retention, though this is a secondary, less-characterized effect compared to the direct bioavailability data above.
Di-magnesium malate
Malate is a tricarboxylic acid cycle intermediate in its own right — which is also the reason it makes sense as the slow-release component.
Human magnesium absorption occurs across the duodenum, jejunum, and ileum, and transporters progressively saturate at higher concentrations — the standard argument for splitting delivery into phases rather than dosing everything at once. The more precise, physiologically grounded version of that argument comes from a single study that measured exactly this.
Timeline of magnesium absorption, in hours
This is the correlating study for the phased-release design: magnesium acetyl taurate was absorbed fastest and reached peak brain concentration quickly, while magnesium malate remained elevated in serum for the longest duration of any compound tested — a genuinely different kinetic profile, not just a different salt. That's a rat pharmacokinetic study, not a human one, but it's the most direct physiological explanation available for pairing fast-absorbing forms in an immediate-release phase with malate held for delayed release.
What kind of evidence backs each form
| Form | Strongest evidence available | Tier |
|---|---|---|
| Albion® Magnesium Bisglycinate | Human RCT — insomnia severity, n=1558 | Human |
| Magnesium Acetyl Taurate | Head-to-head vs. L-threonate, rat model5 | Preclinical |
| Aquamin® Magnesium | Caco-2 bioaccessibility vs. MgO/MgCl₂3 | In vitro |
| Di-Magnesium Malate | Comparative absorption timeline, rat model11 | Preclinical |
Calibrate confidence by form
Only the bisglycinate component currently has a direct human RCT behind it. The acetyl taurate and malate rationale rest on strong, recent, but preclinical (rodent) data, and Aquamin's bioavailability case is in vitro. None of this is a problem — it's an honest and common evidence profile for a newer multi-form system — but the science page copy should reflect that mix rather than imply uniform clinical backing across all four forms.
Also worth confirming: the four-form combination and phased-release format have not been tested together as a finished Magnesium Evolution™ product — each study above tested its ingredient in isolation.
The Magnesium Evolution™ system
Neural & Systemic Support
- Albion® bisglycinate — rapid, well-tolerated systemic repletion
- Magnesium acetyl taurate — fast brain tissue penetration, relaxation pathways
- Aquamin® magnesium — mineral diversity, broad physiological support
Mitochondrial Support
- Di-magnesium malate (DR) — prolonged plasma exposure
- Malate substrate feeds directly into the TCA cycle for ATP production
- Positioned for muscle recovery and sustained mitochondrial function
What the evidence supports — and where it stops
SUPPORTED BY CURRENT EVIDENCE
- Magnesium bisglycinate improves insomnia severity in a real human RCT
- Different magnesium compounds have measurably different absorption timelines and tissue targeting
- Magnesium acetyl taurate outperforms L-threonate on several measures in a head-to-head rat model
- Aquamin-derived magnesium is more bioaccessible than magnesium oxide in vitro
- Magnesium malate shows the most prolonged serum presence of the compounds tested — a physiological rationale for delayed release
NOT YET SHOWN
- Human trials of magnesium acetyl taurate, Aquamin magnesium, or di-magnesium malate specifically
- Direct testing of the four-form, two-phase Magnesium Evolution™ system as a finished product
- That the rat-model acetyl-taurate/L-threonate comparison replicates in humans
The strongest version of this story is a mechanistic one: four forms, four kinetic profiles, one phased-release design built to match how magnesium is actually absorbed and used. That's a defensible, well-reasoned position — it just shouldn't be overstated as uniformly clinical.
Select references
- Ates M, Kizildag S, Yuksel O, Hosgorler F, Yuce Z, Guvendi G, Kandis S, Karakilic A, Koc B, Uysal N. Dose-Dependent Absorption Profile of Different Magnesium Compounds. Biol Trace Elem Res. 2019;192(2):244–251.
- Uberti F, et al. Study of Magnesium Formulations on Intestinal Cells to Influence Magnesium Bioavailability. Nutrients. 2020.
- Felice VD, O'Gorman DM, O'Brien NM, Hyland NP. Bioaccessibility and Bioavailability of a Marine-Derived Multimineral, Aquamin-Magnesium. Nutrients. 2018;10(7):912.
- Dowley A, et al. Bioaccessibility and Tolerability of Marine-Derived Aquamin Magnesium. 2024.
- Kumar A, Mehan S, Gupta S, et al. Enhanced Neurophysiological Benefits of Magnesium-Acetyl-Taurate Over Magnesium-L-Threonate: A Comparative Pre-Clinical Study on Bioavailability, Synaptic Plasticity and Cognitive Functions. Neuromol Med. 2026;28:25.
- Balchem / Albion Minerals. Magnesium Bisglycinate Chelate Technical Monograph.
- Cepeda V, et al. Unlocking the Power of Magnesium: A Systematic Review. 2025.
- Schuster J, Cycelskij I, Lopresti A, Hahn A. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nat Sci Sleep. 2025;17:2027–2040.
- Aquamin®. Magnesium Research Technical Dossier.
- McFarlin BK, et al. Comparing the Bioavailability of Seawater-Derived Magnesium Sources. 2025.
- Uysal N, Kizildag S, Yuce Z, Guvendi G, Kandis S, Koc B, Karakilic A, Camsari UM, Ates M. Timeline (Bioavailability) of Magnesium Compounds in Hours: Which Magnesium Compound Works Best? Biol Trace Elem Res. 2019;187(1):128–136. Added — not in the original source material, but it's the most direct evidence for the immediate/delayed-release rationale.